Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
about
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.Ruxolitinib dose management as a key to long-term treatment success.Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.Ruxolitinib-associated infections: A systematic review and meta-analysis.Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
P2860
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
@ast
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
@en
type
label
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
@ast
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
@en
prefLabel
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
@ast
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
@en
P2093
P1433
P1476
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
@en
P2093
Adrian Duek
Andrei Braester
Anna Courevitch
David Lavie
Elena Mishchenko
Evgeni Chubar
Ilya Kirgner
Martin H Ellis
Najib Dally
P356
10.1016/J.LEUKRES.2015.08.003
P577
2015-08-12T00:00:00Z